Investing.com - Crinetics Pharma (NASDAQ: CRNX) reported third quarter EPS of $-1.01, $0.14 worse than the analyst estimate of $-0.87. Revenue for the quarter came in at $350K versus the consensus estimate of $123.5K.
Crinetics Pharma's stock price closed at $29.52. It is up 78.75% in the last 3 months and up 66.59% in the last 12 months.
Crinetics Pharma saw 2 positive EPS revisions and 4 negative EPS revisions in the last 90 days. See Crinetics Pharma's stock price’s past reactions to earnings here.
According to InvestingPro, Crinetics Pharma's Financial Health score is "fair performance".
Check out Crinetics Pharma's recent earnings performance, and Crinetics Pharma's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar